Side-by-side · Research reference
FOXO4-DRIvsP21
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED12/45 cited
BAnimal-MechanisticHUMAN-REVIEWED8/36 cited
FOXO4-DRI
Senolytic Peptide · D-Retro-Inverso
SQ · Animal models only
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
01Mechanism of Action
Parameter
FOXO4-DRI
P21
Primary target
FOXO4-p53 protein complex in senescent cellsBourgeois 2025Tripathi 2021
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
Pathway
FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
Downstream effect
Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021Alameen 2026
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Feedback intact?
—
—
Origin
D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
Antibody development
—
—
02Dosage Protocols
Parameter
FOXO4-DRI
P21
Animal dose (mouse)
5 mg/kg
SQ injection, aged mouse model (testosterone restoration).
—
Frequency (animal)
Variable — single or intermittent dosing
Protocol-dependent; no standardised regimen.
—
Human equivalent (theoretical)
~0.4 mg/kg (28 mg / 70 kg adult)
Extrapolated using allometric scaling; no clinical validation.
—
Evidence basis
Animal / mechanistic
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
Route
SQ (animal)
No human route established.
Presumed subcutaneous or intraperitoneal (animal studies)
Duration
Weeks to months (animal studies)
Senescent cell clearance observed within weeks.
Not specified
Clinical status
No human trials completed
—
Human dosing
—
No established protocol
No clinical trial data available.
Animal models (mice)
—
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
04Side Effects & Safety
Parameter
FOXO4-DRI
P21
Pulmonary hypertension risk
Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023
—
Context-dependent toxicity
Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023
—
Off-target apoptosis
Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)
—
Immune perturbation
Senescent cells contribute to immune surveillance; clearance effects unknown
—
Human safety unknown
No clinical trials — toxicity profile in humans not established
—
Human safety data
—
None available
No clinical trials in humans.
Animal tolerability
—
Well-tolerated in mouse models; no toxicity reported in available abstracts
Theoretical risks
—
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
Absolute Contraindications
FOXO4-DRI
- ·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
- ·Pregnancy / lactation (no safety data)
P21
- ·Use in humans not validated
Relative Contraindications
FOXO4-DRI
- ·Active malignancy (senescence as tumour suppressor mechanism)
- ·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
05Administration Protocol
Parameter
FOXO4-DRI
P21
1. Pre-clinical route
Subcutaneous injection used in rodent models. No human administration protocol exists.
Not established. No FDA approval, no clinical trial data.
2. Reconstitution (animal)
Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
3. Dosing schedule
Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.
—
4. Clinical development status
No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.
—
5. Safety monitoring (proposed)
Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.
—